|PERNIX THERAPEUTICS HOLDINGS, INC. filed this Form 8-K on 02/19/2019|
9 - Description : Extended - release, fixed dose combination of bupropion HCl and naltrexone HCl indicated for weight loss; represents the market - leading, branded weight loss prescription medication in the U.S. - Strategy : Operated via an SPV called Nalpropion , which Pernix manages in exchange for a fee plus expense reimbursements; marketed via innovative social media and TV campaigns - Loss of Exclusivity: 02/02/2030 (Company is filing patents to extend). Actavis filed an appeal, which is pending. If trial court decision would be reversed, a generic version of Contrave could be launched prior to the expiration of one or more of the patents at issue - Description : Extended release (ER) oral formulation of hydrocodone bitartrate designed with abuse - deterrent technology for the treatment of chronic pain - Strategy : Focus on high potential Pain Specialists and their associated NP/PA providers, highlighting clinical advantages and ease of access through PPD platform - Loss of Exclusivity: Could be as early as 10/1/19 per ongoing litigation matter; otherwise 3/1/2029 - Description : Low dose doxepin for the treatment of insomnia characterized by difficulties with sleep maintenance - Strategy : Promote clinical advantages to high value Psych, PCP and Pain targets, leveraging access through PPD platform with the ability to pursue an OTC switch internally or with an external partner - Loss of Exclusivity: 1/1/2020 - Description : Fixed - dose combination of sumatriptan and naproxen with RT Technology (1) for the treatment of acute migraine attacks - Strategy : Maximize distribution of both Brand and Authorized Generic versions via traditional wholesale markets as well as market share protection via PPD platform - Loss of Exclusivity: 2/15/18 - Description: Portfolio of generic and branded products used for a variety of indications - Strategy: Marketed through Cypress and Macoven through contracts with large and small wholesalers ▪ Product portfolio has generated commercial expertise in pain and other CNS indications with capacity to drive growth and value for additional products [Brand & Authorized Generic] Generics Owned and marketed by Nalpropion Attractive Platform With Leading Pain Franchise 1) RT Technology™ is a rapid release technology used in making TREXIMET ® tablets. This technology enables the tablets to rapidly break apart into small pieces and disperse in the stomach.